Research programme: small molecule therapeutics - Kissei Pharmaceutical/Reborna Biosciences
Latest Information Update: 03 Oct 2024
At a glance
- Originator Kissei Pharmaceutical; Reborna Biosciences
- Class Small molecules
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified